Few things are as simple, accessible, and universal as the act of moving. Walking, breathing faster, feeling your heart speed up. And yet, behind that simplicity, physical exercise holds an extraordinary biological power. In recent years, science has begun to reveal that this everyday action may become one of the most powerful—and underestimated—weapons in the fight against cancer. Beyond merely helping people “feel better” or improving quality of life, exercise appears to have the capacity to profoundly remodel the physiological environment in which cancer develops, directly impacting its progression, recurrence, and, in some cases, even its response to treatment.
This is not an anecdotal finding. In controlled clinical studies, patients with colorectal cancer who participated in structured exercise programs after surgery and chemotherapy showed significant reductions in mortality (37%) and in cancer recurrence (28%) after several years of follow-up. These are not minor figures: they are comparable to those seen with adjuvant pharmacological therapies, but without the associated side effects. In a clinical context where treatment toxicity often poses a major limitation, exercise offers a synergistic alternative that does not destroy but rather builds. It doesn’t intoxicate—it strengthens. And it does so through surprisingly sophisticated mechanisms.
At the immunological level, exercise acts as a natural activator of the body’s tumor surveillance system. When we exercise, we mobilize a number of key immune cells, such as cytotoxic T lymphocytes, natural killer (NK) cells, and dendritic cells, which circulate in greater numbers and with greater effectiveness throughout the body. This mobilization is not trivial: these cells are capable of detecting and destroying abnormal cells before they develop into visible tumors. Moreover, exercise increases the expression of costimulatory molecules and receptors that allow these cells to more precisely identify tumor antigens. In preclinical models, tumors in exercised animals show greater infiltration by functional T cells, translating into a more vulnerable tumor microenvironment.
But the effects of exercise extend far beyond the immune system. It also modifies the body’s inflammatory profile. We know that many tumors thrive in a chronically inflamed environment, where cytokines such as IL-6, IL-1β, and TNF-alpha remain persistently elevated. This low-grade inflammation not only stimulates cell proliferation and the formation of new blood vessels (angiogenesis) but also suppresses key immune functions. Exercise reverses this inflammatory state, lowering the levels of these cytokines and increasing the production of others like IL-10, which has anti-inflammatory properties. It also enhances mitochondrial function and reduces oxidative stress, two crucial factors in preventing DNA damage and, consequently, malignant transformation.
Another fascinating mechanism is related to metabolism. Cancer is largely a disease of metabolic dysregulation. Many tumors depend on glucose as a primary energy source and proliferate more easily in environments where insulin and IGF-1 (insulin-like growth factor) are elevated. Exercise reduces insulin resistance, improves glucose uptake in healthy tissues, and lowers IGF-1 levels, creating a metabolic environment less conducive to tumor growth. In patients with obesity or metabolic syndrome, this can represent a crucial therapeutic advantage, as these states are closely associated with worse oncological outcomes.
The impact of exercise on the gut microbiome should also not be overlooked. In recent years, this bacterial ecosystem has gone from being a background player to one of the protagonists in oncology. It’s been shown that the composition of the microbiome can influence the response to immunotherapy, systemic inflammation, and the production of metabolites that modulate tumor growth. Exercise positively alters the diversity and abundance of beneficial bacteria such as Akkermansia muciniphila and Faecalibacterium prausnitzii, which produce short-chain fatty acids like butyrate. This compound has antitumor, anti-inflammatory, and epigenetic properties, capable of inhibiting cell proliferation and inducing apoptosis in tumor cell lines.
All of these effects occur simultaneously and in a coordinated manner. That is, exercise does not act on a single molecular target, like a conventional drug would. It operates on multiple levels: it regulates immunity, stabilizes metabolism, reduces inflammation, improves tissue oxygenation, enhances cardiovascular efficiency, strengthens muscle mass, improves sleep quality, and reduces psychological stress. Each of these factors directly or indirectly influences cancer development, progression, and control. That is why it is no exaggeration to say that exercise represents an integrated multitarget therapeutic intervention.
Interestingly, a large amount of exercise is not needed to achieve these benefits. Most studies report that between 150 and 180 minutes per week of moderate aerobic activity—such as brisk walking—combined with two or three sessions of muscle strengthening, are sufficient. What matters most is consistency. The key is not intensity, but regularity and continuity. It is sustained bodily movement that creates the internal conditions to resist disease.
Figure 1. Physical activity transforms the tumor microenvironment by enhancing immunity, reducing inflammation, organizing vasculature, and promoting a healthy microbiome—unlike a sedentary lifestyle, which fosters cancer-friendly conditions.
Modern science tells us that exercise should no longer be seen as a superficial or anecdotal recommendation. It should be prescribed, planned, and formally integrated into cancer treatment with the same seriousness as chemotherapy or immunotherapy. Doing so implies a profound transformation of the medical model: it requires the inclusion of physiotherapists, trainers specialized in cancer patients, psycho-oncologists, and nutritionists as part of the therapeutic team. It also requires accessible, funded, and personalized programs tailored to each patient’s capacity. Because not everyone can do the same, but everyone can move.
In essence, exercise is medicine without pills. A form of endogenous immunotherapy. A physiological modulator capable of empowering the human body to resist, repair, and fight cancer from within. It does not compete with conventional treatments—it complements them. It does not replace medicine—it enriches it. And the best part is that it is available here and now, within reach of millions of people facing this disease with the hope of finding new answers. Perhaps, in movement, many of those answers are already on the way.
Main Reference:
Courneya, K. S., Vardy, J. L., O’Callaghan, C. J., Gill, S., Friedenreich, C. M., Wong, R. K. S., Dhillon, H. M., Coyle, V., Chua, N. S., Jonker, D. J., Beale, P. J., Haider, K., Tang, P. A., Bonaventura, T., Wong, R., Lim, H. J., Burge, M. E., Hubay, S., Sanatani, M., Campbell, K. L., … CHALLENGE Investigators (2025). Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. The New England journal of medicine, 393(1), 13–25. https://doi.org/10.1056/NEJMoa2502760
Other References:
Pedersen, L., Idorn, M., Olofsson, G. H., Lauenborg, B., Nookaew, I., Hansen, R. H., Johannesen, H. H., Becker, J. C., Pedersen, K. S., Dethlefsen, C., Nielsen, J., Gehl, J., Pedersen, B. K., Thor Straten, P., & Hojman, P. (2016). Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. Cell metabolism, 23(3), 554–562. https://doi.org/10.1016/j.cmet.2016.01.011
Koelwyn, G. J., Quail, D. F., Zhang, X., White, R. M., & Jones, L. W. (2017). Exercise-dependent regulation of the tumour microenvironment. Nature reviews. Cancer, 17(10), 620–632. https://doi.org/10.1038/nrc.2017.78
